Treatment of periodic leg movement disorder and restless leg syndrome with talipexole.
In order to investigate the bedtime dose of talipexole, a D2 and alpha2 stimulant, on patients with periodic leg movement disorder (PLMD) and restless leg syndrome (RLS), we made a comparison of polysomnographic findings and subjective symptom ratings before and during 4 weeks of the treatment on five cases with RLS and PLMD. A significant decrease in both the frequencies of periodic leg movements and subjective symptom ratings and significant improvement of sleep composition were recognized during the treatment. We speculate that the combination of the agonistic action of D2 and alpha2 receptor with the drug might not only suppress PLMD and RLS but also improve sleep quality.
Inoue
Y
Y
Department of Neuropsychiatry, Faculty of Medicine, Tottori University, Japan.
Mitani
H
H
Nanba
K
K
Kawahara
R
R
D001381:Azepines / Q000008:administration & dosage* / Q000009:adverse effects; D018491:Dopamine Agonists / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017286:Polysomnography / Q000187:drug effects; D012148:Restless Legs Syndrome / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D012894:Sleep Stages / Q000187:drug effects; D016896:Treatment Outcome
D001381:Azepines; D018491:Dopamine Agonists; C024763:talipexole